Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque - A 3-dimensional intravascular ultrasound study

Hiroaki Takashima, Yukio Ozaki, Tatsuya Yasukawa, Katsuhisa Waseda, Kenji Asai, Yoshinori Wakita, Yasuo Kuroda, Takashi Kosaka, Yasushi Kuhara, Takayuki Ito

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Background: Recent lipid-lowering trials have reported that statin therapy may retard progression or stimulate regression of human coronary plaque. In the present study volumetric intravascular ultrasound (IVUS) analyses were performed to investigate the effect of pitavastatin, a newly developed statin, on regression of human coronary plaque. Methods and Results: Eighty-two patients matched for age and gender from 870 consecutive patients undergoing IVUS guided percutaneous coronary intervention were retrospectively assigned to either lipid-lowering therapy (n=41; pitavastatin 2 mg/day) or control group (n=41; diet only). Serial volumetric IVUS analyses of a matched left main coronary arterial site were performed. A significant reduction in low-density lipoprotein-cholesterol (LDL-C) level of 33.2% (p<0.001) was observed in the pitavastatin group. Plaque volume index (PVI) was significantly reduced in the pitavastatin group (10.6±9.4% decrease) compared with the control group (8.1±14.0% increase, p<0.001). There were positive correlations between the percent change in the PVI and follow-up LDL-C level (r=0.500, p<0.001) and the percent change in LDL-C level (r=0.479, p<0.001). Conclusion: Lipid-lowering therapy with pitavastatin induced significant coronary plaque regression, associated with a significant reduction in the LDL-C level. The percent change in the PVI showed a significant positive correlation with the percent change in LDL-C level.

Original languageEnglish
Pages (from-to)1678-1684
Number of pages7
JournalCirculation Journal
Volume71
Issue number11
DOIs
Publication statusPublished - 17-12-2007

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Atherosclerotic Plaques
LDL Cholesterol
Lipids
Therapeutics
Control Groups
Percutaneous Coronary Intervention
pitavastatin
Diet

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Takashima, Hiroaki ; Ozaki, Yukio ; Yasukawa, Tatsuya ; Waseda, Katsuhisa ; Asai, Kenji ; Wakita, Yoshinori ; Kuroda, Yasuo ; Kosaka, Takashi ; Kuhara, Yasushi ; Ito, Takayuki. / Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque - A 3-dimensional intravascular ultrasound study. In: Circulation Journal. 2007 ; Vol. 71, No. 11. pp. 1678-1684.
@article{2d4e60e4b1584c249fa363cbb3d4eff4,
title = "Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque - A 3-dimensional intravascular ultrasound study",
abstract = "Background: Recent lipid-lowering trials have reported that statin therapy may retard progression or stimulate regression of human coronary plaque. In the present study volumetric intravascular ultrasound (IVUS) analyses were performed to investigate the effect of pitavastatin, a newly developed statin, on regression of human coronary plaque. Methods and Results: Eighty-two patients matched for age and gender from 870 consecutive patients undergoing IVUS guided percutaneous coronary intervention were retrospectively assigned to either lipid-lowering therapy (n=41; pitavastatin 2 mg/day) or control group (n=41; diet only). Serial volumetric IVUS analyses of a matched left main coronary arterial site were performed. A significant reduction in low-density lipoprotein-cholesterol (LDL-C) level of 33.2{\%} (p<0.001) was observed in the pitavastatin group. Plaque volume index (PVI) was significantly reduced in the pitavastatin group (10.6±9.4{\%} decrease) compared with the control group (8.1±14.0{\%} increase, p<0.001). There were positive correlations between the percent change in the PVI and follow-up LDL-C level (r=0.500, p<0.001) and the percent change in LDL-C level (r=0.479, p<0.001). Conclusion: Lipid-lowering therapy with pitavastatin induced significant coronary plaque regression, associated with a significant reduction in the LDL-C level. The percent change in the PVI showed a significant positive correlation with the percent change in LDL-C level.",
author = "Hiroaki Takashima and Yukio Ozaki and Tatsuya Yasukawa and Katsuhisa Waseda and Kenji Asai and Yoshinori Wakita and Yasuo Kuroda and Takashi Kosaka and Yasushi Kuhara and Takayuki Ito",
year = "2007",
month = "12",
day = "17",
doi = "10.1253/circj.71.1678",
language = "English",
volume = "71",
pages = "1678--1684",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "11",

}

Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque - A 3-dimensional intravascular ultrasound study. / Takashima, Hiroaki; Ozaki, Yukio; Yasukawa, Tatsuya; Waseda, Katsuhisa; Asai, Kenji; Wakita, Yoshinori; Kuroda, Yasuo; Kosaka, Takashi; Kuhara, Yasushi; Ito, Takayuki.

In: Circulation Journal, Vol. 71, No. 11, 17.12.2007, p. 1678-1684.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque - A 3-dimensional intravascular ultrasound study

AU - Takashima, Hiroaki

AU - Ozaki, Yukio

AU - Yasukawa, Tatsuya

AU - Waseda, Katsuhisa

AU - Asai, Kenji

AU - Wakita, Yoshinori

AU - Kuroda, Yasuo

AU - Kosaka, Takashi

AU - Kuhara, Yasushi

AU - Ito, Takayuki

PY - 2007/12/17

Y1 - 2007/12/17

N2 - Background: Recent lipid-lowering trials have reported that statin therapy may retard progression or stimulate regression of human coronary plaque. In the present study volumetric intravascular ultrasound (IVUS) analyses were performed to investigate the effect of pitavastatin, a newly developed statin, on regression of human coronary plaque. Methods and Results: Eighty-two patients matched for age and gender from 870 consecutive patients undergoing IVUS guided percutaneous coronary intervention were retrospectively assigned to either lipid-lowering therapy (n=41; pitavastatin 2 mg/day) or control group (n=41; diet only). Serial volumetric IVUS analyses of a matched left main coronary arterial site were performed. A significant reduction in low-density lipoprotein-cholesterol (LDL-C) level of 33.2% (p<0.001) was observed in the pitavastatin group. Plaque volume index (PVI) was significantly reduced in the pitavastatin group (10.6±9.4% decrease) compared with the control group (8.1±14.0% increase, p<0.001). There were positive correlations between the percent change in the PVI and follow-up LDL-C level (r=0.500, p<0.001) and the percent change in LDL-C level (r=0.479, p<0.001). Conclusion: Lipid-lowering therapy with pitavastatin induced significant coronary plaque regression, associated with a significant reduction in the LDL-C level. The percent change in the PVI showed a significant positive correlation with the percent change in LDL-C level.

AB - Background: Recent lipid-lowering trials have reported that statin therapy may retard progression or stimulate regression of human coronary plaque. In the present study volumetric intravascular ultrasound (IVUS) analyses were performed to investigate the effect of pitavastatin, a newly developed statin, on regression of human coronary plaque. Methods and Results: Eighty-two patients matched for age and gender from 870 consecutive patients undergoing IVUS guided percutaneous coronary intervention were retrospectively assigned to either lipid-lowering therapy (n=41; pitavastatin 2 mg/day) or control group (n=41; diet only). Serial volumetric IVUS analyses of a matched left main coronary arterial site were performed. A significant reduction in low-density lipoprotein-cholesterol (LDL-C) level of 33.2% (p<0.001) was observed in the pitavastatin group. Plaque volume index (PVI) was significantly reduced in the pitavastatin group (10.6±9.4% decrease) compared with the control group (8.1±14.0% increase, p<0.001). There were positive correlations between the percent change in the PVI and follow-up LDL-C level (r=0.500, p<0.001) and the percent change in LDL-C level (r=0.479, p<0.001). Conclusion: Lipid-lowering therapy with pitavastatin induced significant coronary plaque regression, associated with a significant reduction in the LDL-C level. The percent change in the PVI showed a significant positive correlation with the percent change in LDL-C level.

UR - http://www.scopus.com/inward/record.url?scp=36949023811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36949023811&partnerID=8YFLogxK

U2 - 10.1253/circj.71.1678

DO - 10.1253/circj.71.1678

M3 - Article

C2 - 17965484

AN - SCOPUS:36949023811

VL - 71

SP - 1678

EP - 1684

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 11

ER -